Figure 3.

Cost-effectiveness acceptability curve for adults (top): For any willingness to pay (WTP) per additional diagnosis above $8650, there is more than 95% probability that whole-exome sequencing (WES) is cost-effective compared with standard diagnostic pathway; for a WTP threshold above $6950, the probability of WES being cost-effective is above 80%. Children (bottom): For any WTP per additional diagnosis above $950, there is more than 95% probability that WES is cost-effective compared with standard diagnostic pathway. CE, cost-effectiveness.